Amphastar Pharmaceuticals, Inc. AMPH
26.13
(0.14)
(0.53%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 15.0×
Follow AMPH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
14.84% | 12.90% | 10.39% | 10.30% | |
| 6.95% | 6.12% | 4.84% | 4.68% | ||
ROIC |
8.46% | 7.88% | 6.69% | 6.57% | |
Return on Tangible Assets |
15.03% | 12.44% | 10.20% | 11.49% | |
Average Days of Receivables |
75.13 | 81.49 | 79.76 | 73.74 | |
Free Cash Flow per Share |
2.39 | 2.54 | 2.98 | 3.50 | |
Free Cash Flow |
110.85 | 118.83 | 135.19 | 152.89 | |
Capital Expenditures |
(41.42) | (37.28) | (33.69) | (31.72) | |
Piotroski F-Score |
4.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
9.15% | 9.27% | 10.06% | 11.04% | |
Accounts Receivable Turnover |
4.92 | 4.82 | 4.76 | 5.18 | |
Accounts Payable Turnover |
2.13 | 2.38 | 2.31 | 1.83 | |
Inventory Turnover |
2.32 | 2.20 | 2.13 | 2.06 | |
Average Days of Payables |
190.18 | 148.83 | 146.89 | 240.24 | |
Days of Inventory on Hand |
185.29 | 177.46 | 163.73 | 171.94 | |
Tax Rate |
(0.18) | (0.21) | (0.23) | (0.23) | |
Research and Development Expense of Revenue |
11.15% | 11.92% | 12.84% | 12.95% | |
Selling, General and Administrative Expense of Revenue |
17.48% | 18.03% | 18.31% | 19.08% | |
Share Based Compensation of Revenue |
3.69% | 3.79% | 3.91% | 3.95% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.36 | 1.59 | 2.13 | 2.35 | |
Depreciation/Fixed assets |
0.19 | 0.19 | 0.20 | 0.19 | |
Capex/Depreciation |
(0.70) | (0.62) | (0.55) | (0.52) | |
Revenue per Share |
15.56 | 15.40 | 15.90 | 16.73 | |
Operating CF per Share |
3.28 | 3.34 | 3.73 | 4.23 | |
Capex per Share |
(0.89) | (0.80) | (0.74) | (0.73) | |
Capex to Sales |
0.06 | 0.05 | 0.05 | 0.04 | |
Net Profit Margin |
15.43% | 13.63% | 11.00% | 10.76% |
Columns are period end dates